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ABSTRACT 
 
 Multiple Myeloma (MM) is a treatable, yet incurable, malignancy of bone marrow 
plasma cells. This cancer affects many patients and many succumb to relapse of tumor burden 
despite a large number of available chemotherapeutic agents developed for therapy.  This is 
because MM tumors are heterogeneous and receive protection from therapeutic agents by the 
microenvironment and other mechanisms including homologous MM-MM aggregation. 
Therefore, therapy failure and frequent patient relapse is due to the evolution of drug resistance, 
not a lack of available drugs. To analyze and understand this problem, the evolution of drug 
resistance has been explored and presented herein. We seek to describe the methods through 
which MM cells become resistant to therapy, and how this resistance evolves throughout a 
patient’s treatment history. We achieve this in five steps. First	we	 review	 the	patient’s	 clinical	 history,	 including	 treatments	 and	 changes	 in	tumor	 burden. Second,	 we	 trace	 the	 evolutionary	 tree	 of	 sub-clones	 within	 the	 tumor	burden	 using	 standard	 of	 care	 fluorescence	 in	 situ	 hybridization	 (FISH). Thirdly, 
immunohistochemistry slides are stained and aligned to quantify the level of environmental 
protection received by surrounding cells and plasma in the bone marrow microenvironment 
(coined environment mediated drug resistance score [EMDR]). The fourth analysis type is 
produced through a novel 384-well plate ex vivo chemosensitivity assay to quantify sensitivity of 
primary MM cells to chemotherapeutic agents and extrapolate these findings to 90-day clinical 
response predictions. In addition to direct clinical application in the choice of best treatment, this 
tool was also used to study changes in sensitivity of patient tumors to other drugs, and it was 
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observed that, upon relapse, in addition to developing resistance to the current line of therapy, 
tumors become cross-resistant to agents that they were never exposed to. Finally, MM-MM 
homologous aggregation is quantified to assess the level of drug resistance contributed by 
clustering of patient tumor cells, which causes upregulation of Bcl-2 expression and other 
resistance mechanisms1. 
The findings of such experimentation improve comprehension of the driving factors that 
contribute to drug resistance evolution on a personalized treatment basis. The aforementioned 
factors all contribute in varying degrees for unique patient cases, seven of which are presented in 
depth for this project. In summary: Environmental protection plays a critical initial role in drug 
resistance, which is followed by increase in tumor genetic heterogeneity as a result of mutations 
and drug-induced Darwinian selection. Eventually, environment-independent drug resistant sub-
populations emerge, allowing the tumor to spread to unexplored areas of the bone marrow while 
maintaining inherited drug resistant phenotype2. It is our hope that these findings will help in 
shifting perspective regarding optimal management of MM by finding new therapeutic 
procedures that address all aspects of drug resistance to minimize chance of relapse and improve 
quality of life for patients. 
	 1 
 
 
 
 
 
CHAPTER 1:  INTRODUCTION 
 
Multiple Myeloma (MM) is an incurable cancer of the bone marrow. Despite many 
available treatment options, prognosis remains quite poor and relapse occurs in many patients3. 
This relapse is known to occur due to genetic mutations that can lead to high risk tumor 
subpopulations4,5, changes in the tumor microenvironment6,7, and changes in phenotypic 
interaction by MM-MM cell adhesion/interaction8. High-risk patients have a low median overall 
survival (<2 years) despite the approval of many new drugs. This suggests that the problem is not 
lack of drugs but our lack of knowledge of how tumors evade therapy and develop drug 
resistance. Our goal, therefore, is to delay the rate of evolution of drug resistance and increase 
patient survival by one order of magnitude, reaching a functional cure. We seek here to further 
quantify the mechanisms of drug resistance and assess how they evolve throughout the course of 
therapy. This project aims to quantify the evolution of drug resistance across sequential biopsies 
of seven patients with respect to genetic abnormality, ex vivo response prediction, EMDR, and 
homologous MM-MM adhesion. First, we seek to understand the genetic abnormalities that drive 
drug resistance evolution. 
Complex and multiple chromosomal abnormalities present themselves in the plasma cells 
of MM4,5,9. MM karyotypes can be analyzed for these abnormalities by means of interphase 
fluorescence in situ hybridization (FISH), which can analyze the chromosomes of non-dividing 
cells5,9-11. FISH probes are utilized in pairs and primarily apply to studies of monosomies/ 
trisomies, changes in chromosomes 17 and 13, and translocations of the immunoglobulin heavy-
chain locus. This is due to the high clinical risk of poor prognosis typically associated with these 
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abnormalities, including the translocations of 14q32 (IGH) and 11q13 (CCND1) which causes 
overexpression of CCND1 and cell cycle dysregulation, and IGH translocation with 4p16 
(FGFR3) which causes overexpression of MMSET leading to apoptosis prevention3,12-18. There is 
an additional risk associated with a deletion of chromosome 13, which promotes clonal 
expansion and is associated with hypodiploid MM, though there is no one specific genetic 
consequence of alterations to this chromosome12. 
FISH tests for these high-risk abnormalities, and thus not all genetic abnormalities are 
portrayed in a FISH panel. In subsequent discussion of clonal dynamics, care must be taken to 
define what is meant by a clone. The term clone, as it is presented here, refers to an identical 
group of cells with respect to MM-FISH report results. It is unknown if these cells are truly 
identical in areas other than genetic mutation detectable by the FISH probes. The chromosomal 
abnormalities detected play a variety of roles in drug resistance through deregulation of crucial 
proteins as discussed above. However, analysis of FISH alone as an indicator of drug resistance 
in MM remains insufficient, as patients with the same genetic abnormalities commonly have 
different clinical results19-21. We expect this is due to a multitude of additional factors including 
therapeutic intervention, environment-mediated drug resistance (EMDR), and MM homologous 
aggregation. 
Another way to assess the changes in drug resistance throughout a patient’s treatment 
history is to utilize the ex vivo results of experiments we performed using primary patient cells. 
This 96-hour well plate experiment allows us to quantify the continuous viability of cells 
obtained through bone marrow aspirates at Moffitt Cancer Center22. Through computational 
techniques utilizing pharmacokinetic models published for therapeutic agents, extrapolation of 
dose response can yield accurate predictions of clinical response for individual patients. These 
3 
results may be used to analyze drug resistance upon relapse and shows strong patterns of cross-
resistance across the panel of chemotherapeutic agents. This data, though based on phenotype, 
may be used in conjunction with genetic mutation information to glean further into the evolution 
of drug resistance in MM. However, there are further methods that may be employed to continue 
broadening the scope of analysis to this end. 
Environment mediated drug resistance (EMDR) is a term used to describe the bone 
marrow (BM) microenvironment’s promotion of cell survival to therapy, and consequent 
contribution to minimal residual disease, through a variety of soluble and adhesive factors23-28. 
One such physical factor, fibronectin (FN) is known to control survival and growth of MM 
cells29. FN has been determined to play a prominent role in growth and drug resistance control in 
MM due to the promoted secretion of the cytokine interleukin (IL)-624,29,30. FN adhesion to MM 
cells causes activation of integrin heterodimers composed of integrins α4 or α5 and β1 through 
intracellular signaling via protein tyrosine kinases (PTK) and receptor PTK31,32. Here, we 
propose a metric to assess the level of EMDR in MM patients through co-localization of MM 
membrane-bound β1 integrins and FN using immunohistochemistry (IHC) and digital image 
analysis. This approach generates frequency distributions of the tumor burden and the degree of 
EMDR protection to which they are submitted. If EMDR is a clinically relevant mechanism, 
sequential biopsies should depict changes in these levels in accordance with increases in drug 
resistance. 
In addition to extracellular matrix- and stroma-derived factors, homologous (cell-cell) 
adhesion also promotes drug resistance in hematologic tumors1,33. The formation of aggregates 
among tumor cells (via 1.5% agarose solution in 96-well plates) has been shown to promote 
resistance to drugs including Bortezomib and Doxorubicin through an increase in the level of 
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Bcl-2, an anti-apoptotic protein1. Additionally, in solid tumors, the density of cell clusters poses 
a barrier to drug penetration by affecting magnitude of diffusion gradients that improves drug 
resistance with the formation of more compact, less invasive tumors33-36. Concurrently, the case 
of decreased cell proliferation in multicellular spheroids of pancreatic cancer has been shown to 
improve drug resistance through associated cascades in cell survival signaling, including cyclin-
CDK (cyclin-dependent kinases), which regulates progression through the cell cycle and allows 
DNA injuries and chromosomal defects to be repaired37-39. The progression of tumor clustering 
throughout patient treatment has also been observed in MM40. A known cause of MM clustering 
is the expression of β-catenin that stimulates overexpressed signaling of Wnt, a paracrine growth 
factor that can influence MM growth41,42. It has been determined that N-cadherin is consequently 
over-expressed as the extracellular counterpart to β-catenin, and patient primary cells with high 
expression of CDH2 (the gene that encodes N-cadherin) correlates with a high probability 
(>83%) of high-risk genetic abnormalities such as t(4;14)(p16;q32) translocations and CCND1 
(11q13) duplication, though the cause of the correlation between these two mechanisms of drug 
resistance remains unknown43,44. These abnormalities suggest poor prognosis for MM patients, 
and further strengthens the correlation between homologous adhesion of MM cells and drug 
resistance. Analysis of primary MM cell clustering due to MM-MM adhesion can provide 
additional insight into the evolution of drug resistance in patients.  
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Human Subjects/Clinical History 
Redacted patient histories were obtained through the Total Cancer Care (TCC) Initiative 
at Moffitt Cancer Center. Name, age, and gender were removed from provided data to comply 
with anonymity of patients from researchers. However, blood test results showing tumor 
progression through serum free light chain (SFLC) and M-spike levels, as well as biopsy dates 
and therapeutic regimen utilized were all provided kindly by the Moffitt hospital. 
 
2.2 Cell Lines and Primary Cell Protocols 
Our previous work delves greatly into the procedures through which cell lines and 
primary patient cells were obtained and utilized ex vivo45. H929 and MM1s MM cell lines were 
cultured and utilized as positive control in ex vivo protocols. Primary cells from patients were 
obtained through the TCC initiative and magnetic bead sorted to select for CD138+ primary MM 
cells. 
 
2.3 Ex vivo Procedures and Imaging 
Additional work we have compiled and published in the Silva laboratory divulge great 
detail in the seeding of cells ex vivo, the equipment utilized, and the software composed in house 
to extrapolate experiment therapy response to clinical prediction46. Primary cells/cell lines are 
seeded in a 384 well plate with collagen and patient stroma to replicate the bone marrow 
microenvironment. Once incubated and spun to the same focal plane, drugs at relevant densities 
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(up to 31 plus control) were added to the plate and time-lapse imaging was run for 96 hours 
(image acquisition every 30 minutes). These results were then extrapolated to determine 
maximum tumor burden levels at 90-day clinical response for each patient utilizing 
pharmacokinetics and parameterization of evolutionary models with ex vivo results. 
 
2.4 FISH and Phylogenetic Analyses 
FISH reports are provided in a revised format by the Moffitt Cancer Center. First, we 
determine which probe results are abnormal from the Specific Probe Results report section, and 
which ones are mutually exclusive of each other based on chromosomal location. Care must be 
taken to realize that some abnormal results without translocation may simply be artifacts of a 
different probe analysis since they are always done in pairs. From the principle of maximum 
parsimony we expect that clonal dynamics of the tumor will follow the most ‘straight-line’ path 
in terms of the phylogenetic tree. This also suggests a much more increased likelihood of 
additional mutations presenting themselves stepwise through time, rather than the appearance 
and disappearance of multiple abnormalities from subpopulations. We compare FISH reports 
from sequential patient biopsies and create the tree based on these principles rather than 
chronological emergence. The results are an understanding of the percentage of tumor burden 
over time that contains the high-risk abnormalities tested in FISH and the phylogenetic tree of 
these abnormal clone subpopulations. If these principles are not followed in clonal dynamic 
determination, phylogenetic trees and subsequent results become overcomplicated and unclear. A 
detailed diagram for proper FISH report analysis is presented in Figure 2.1. 
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2.5 EMDR Score Determination and Calculation 
EMDR score is based on bone marrow immunohistochemistry. Slides are requested and 
provided by the Moffitt Tissue Core for integrin β1, FN, and CD138 with corresponding positive 
and negative controls. All provided slides are scanned by the Moffitt Cancer Center Microscopy 
Core at up to 20x magnification and cropped and aligned manually to the best of the user’s 
ability in ImageJ. Our macro takes the slides and completes their alignment to overlay pixels of 
each subsequent slide.  The CD138 threshold value is determined based on the positive control 
slide and the average value of all negative control slides is stored as a noise mitigation constant 
to be subtracted from all future images. The aligned CD138 image is turned into a mask of zeros 
and ones, so that only myeloma-containing areas have numerical value.  The FN and β1 8-bit 
images are overlaid and multiplied by the CD138 mask to allow for a maximum value of 65,025. 
The square root of this data set (maximum value of 255) is the EMDR score. In addition to this 
score, algorithms utilizing nearly identical processes are run to create the scores of FN and β1 in 
their respective slides, including areas with and without MM (CD138) and the slide as a whole. 
A detailed diagram of the EMDR computational process is presented in Figure 2.2. 
 
2.6 Cluster/Aggregation Determination 
The clustering of MM cells from patient primary samples is analyzed throughout 
patients’ histories to further explore mechanisms of drug resistance. Four replicate images of 
control wells from the aforementioned ex vivo assay46 at time point zero, imaged in phase 
contrast at 5x magnification, are saved and quantified to determine the number of neighbors that 
each live cell has within a 20-pixel diameter. This diameter was chosen with care to ensure a 
window that is large enough to capture multiple cells, but not large enough to count cells that are 
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un-clustered or far apart. The typical MM patient primary cell is 5-8 pixels in diameter. The 
mean number of neighbors for each cell in the well is a straight forward and accurate way to 
quantify the phenotypic clustering that can occur in patient samples (such as in case 2). In 
supplementation of these results, a cohort of 11 patients were quantified for number of neighbors 
and plotted versus the sum of the area under the curves from our ex vivo assay (Silva et al. In 
review). A graph is synthesized for each drug in this manner to determine if any linear 
correlation exists between therapy resistance and the phenotypic clustering we seek to further 
understand. 
 
2.7 Chapter Two Figures 
Figure 2.1: Flow of Information: FISH Report Analysis. Flow of information for analysis of 
FISH reports and determination of phylogeny of tumor subpopulations for each patient and the 
extrapolation of this information to determine clonal dynamics. 
 
Initial Report 
Analysis 
• From MM-FISH Reports, determine what abnormalities are present across 
patient biopsies.  
• Determine which biopsies must be mutually exclusive based on 
chromosomal location. 
Abnormalities 
to clones 
• Following the principle of maximum parsimony, expect the most ‘straight-
line’ path of genetic mutation, realizing that emergence is more likely to be 
based on complexity rather than chronology. 
• Group the tumor burden by percentage across the biopsies to determine the 
most likely mutation paths. 
Phylogenetic 
Tree Synthesis 
• Label these clones and map the phylogenetic tree that most likely represents 
the FISH report in its entirety. 
• Note that unknown percentages are not necessarily normal, they are untested 
by standard of care FISH probes. 
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Figure 2.2: Flow of Information: EMDR Analysis. Algorithmic procedure for determining 
EMDR score for each patient biopsy. This outline is designed to contribute to holistic 
understanding of the ImageJ macro, as all steps once run are automatic. 
 
  
Noise 
Mitigation 
• Prompt to select control images location. 
• Use positive CD138 control to determine threshold level of MM detection. 
• Determine average background noise value from all negative controls and subtract this value 
from all future images. 
Alignment 
• Prompt to select the cropped patient slides location. 
• Open first two slides and run images to stack and align via Rigid Body transformation 
• Run stack to images and add all slides one by one, repeating the transformation until all slides 
are properly aligned. 
EMDR Score 
Calculation 
• Transform CD138 aligned slide into a mask, representing MM-present pixels as ones and all 
other pixels as zeros. 
• Multiply the aligned FN and Beta1 values to this mask, taking the square root of the result. This 
is the EMDR score. 
• Repeat this process, reversing the mask to represent non-MM pixels and determine the scores 
similarly. 
• Finally, do not use the mask and ascertain the intensity of the whole slides to FN and Beta1. 
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CHAPTER 3:  RESULTS 
 
3.1 Clinical Relapse is Followed by Tumor Population Turnover 
Analysis of tumor phylogeny across patient clinical history provides insight into the 
development and progression of tumor cell heterogeneity and drug resistance. The case shown in 
Figure 3.1 presents a patient treated over nearly 80 months (case 1). The serum free light chain 
(SFLC) measurement throughout the course of treatment is presented with therapy regimen in 
panel A. Four sequential relapse events occur between bone marrow biopsy (BMBx) 1 and 7, 
with a sharp relapse spike in SFLC from BMBx 7 to 8 that remains relatively consistent through 
the remaining two biopsies (9 and 10). MM-FISH reports from these biopsies may be analyzed 
and interpreted to generate clonal dynamic and phylogenetic tree representations. 
This patient has a fairly complex phylogenetic tree (Figure 3.1C). Starting from clones 1 
through 3, subsequent clones contain the same abnormalities as their predecessors with 
additional mutations, creating more complex tumor subpopulations. For example, from clone 1.1 
to 1.2, an additional translocation of 11q and 14q presents itself, and from clone 3.2 to 3.2.1, a 
deletion of the 14q chromosome appears. Clonal dynamics seen in Figure 3.1B appear minimal 
until bone marrow biopsy (BMBx) 8, which is matched by a sharp spike in tumor burden (Figure 
3.1A). From this point onward, more complex clones tend to take the place of their ‘parent’ 
clones. This behavior can also be seen in cases 3 and 4 (Supplemental Figures A.5 and A.7 
respectively). 
Case 3 has a steadily increasing tumor burden that is accompanied by clonal dynamic 
shifts. We see from Figure A.5F that the phylogeny is one straight line, and Figure A.5D shows 
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that from BMBx1 to 3, clone 1.1 is steadily overtaking clone 1, and clone 1.1.1 emerges rapidly 
between biopsies 2 and 3. Case 4 shows similar results (Figure A.7D). From BMBx1 to 2, clone 
1 is overtaken by daughter clones 1.1 and 1.2. From BMBx 2 to 3, clone 1.1 remains present 
while clone 1.2.1 begins to overtake its parent clone (clone 1.2). Case 7 represents a 
straightforward phylogeny with only one clone containing one abnormality (Supplemental Figure 
A.11). From BMBx 2 to 4 in this case, while undergoing no treatment, the tumor appears to 
relapse slowly with a concurrent growth rate of clone 1, suggesting that these cells have some 
sort of survival advantage over the non-mutated remainder. Case 5 presents an interesting 
phenomenon of reemergence of a previously undetected parent clone (Supplemental Figure A.8). 
In fact, clone 1 is not detected until BMBx4, while daughter clones portray expected behavior in 
the first two biopsies. This is also seen in Figure 3.1 with respect to Clone 1. 
 
3.2 Chemotherapeutic Intervention Can Lead to Cross-Resistance for Subsequent Therapy 
 From panels A, C, and E of Figure 3.2 we see that between biopsies 8 and 10, despite the 
lack of a significant tumor burden change, the predicted tumor burden decrease is significantly 
higher for Bortezomib, Melphalan, and CRM1i. This cross-resistance occurs while the patient is 
treated with TH-302, Bortezomib, and Dexamethasone. From panels B, D, and F, we see there is 
treatment between biopsies 3 and 5 of TH-302, Bortezomib, and Dexamethasone as well, 
however there is an increase only in Melphalan resistance. This suggests that treatment given 
does not result in similar resistance changes for different patients. However, it is important to 
note that in all cases encountered during which resistance evolves, there is a marked increase in 
resistance to drugs that patients have not been exposed to, suggesting that resistance occurs by 
mechanisms that are not unique to one or even a few particular drugs. 
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3.3 Environmental Protection Changes with Tumor Burden and Cell Location 
Analysis of EMDR can provide insight into the extent and progression of environmental 
protection MM cells are receiving throughout patient therapy. References to FN score and β1 
score refer to the CD138-positive regions (blue lines). Figure 3.3 represents a case (case 2) for 
which patient response was tracked over nearly 40 months with tumor burden measured using 
sM-spike (Figure 3.3A). We see a steady increase in disease progression from BMBx1 to 3 with 
a sharper increase from BMBx 3 to 4, leveling out by BMBx 5. It is observed that EMDR score 
(Figure 3.3B) increases from BMBx1 to 2, and decreases from BMBx2 onward. FN and β1 
scores share the same behavior (Figure 3.3B and 3.3C respectively), though FN score decreases 
to a greater extent, falling below even the healthy tissue expression levels. This trend of EMDR 
score increase during lower tumor burden levels and EMDR decrease during spikes in tumor 
burden is also present in Supplemental Figure A.1 (case 1), where EMDR is consistently 
increasing until BMBx 8 at which point there is a dramatic raise in SFLC level. For the 
remaining two biopsies, EMDR score decreases. Cases 3, 4, and 5 show no significant change in 
EMDR score across sequential biopsies (Supplemental Figures A.5, A.7, and A.8). 
 
3.4 Alternative Mechanisms of Resistance: Clustering  
After analysis of clonal dynamics and EMDR for several cases, we noticed that when 
compared to our ex vivo results, the variability in cross resistance and sensitivity to drugs varied 
between cases 1 and 2, despite being on the same course of treatment (TH302/BTZ/DEX). We 
expect, therefore, that there is another mechanism of drug resistance left to explore. In further 
analysis of the ex vivo results, we took a look at the images utilized in patient response 
prediction and observed an increase in clustering of MM patient cells in case 2, but not in case 1. 
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Based on this finding, we developed a novel ‘number of neighbors’ algorithm to quantify the 
phenotypic change of patient cell locations and clustering once seeded in the 384-well plate. 
Cases 1 and 2 are represented in Figure 3.4A-D. Case 1 (Figure 3.4A and C), from BMBx 8-10 
had previously shown a dramatic spike in tumor burden, and stays relatively constant during this 
time. The FISH clones appear very complex and show complete population progression of 
subpopulations with more chromosomal abnormalities. The ex vivo results for case 1 show 
dramatic increase in resistance to both Melphalan and Bortezomib from BMBx 8 to BMBx 10 
(Figure 3.2C and E). EMDR begins decreasing over this time period as well (Supplemental 
Figure A.1). Clustering of MM primary cells during this time frame, however, appear stagnant 
and minimal. The same is observed in case 3, however the tumor burden in this case is 
continuously increasing from BMBx 1 to 4 (Supplemental Figure A.5A and A.6), with less 
dramatic but still significant change in FISH dynamics as clone 1.1 overcomes clone 1 and clone 
1.1.1 emerges as the most fit genetic variation. In case 3, EMDR remains constant across all 
biopsies (Figure A.5) and according to ex vivo results (Figure A.6), there is an increased 
sensitivity to Melphalan and a steady increase in resistance to Carfilzomib. 
In contrast to cases 1 and 3, cases 2 and 6 (Figures A.4 and A.10 respectively) show 
significant increase in clustering across sequential biopsies. While FISH, ex vivo, and EMDR 
results are unavailable for case 6, we see a response to drug, followed by relapse between 
biopsies one and two, which is accompanied by an increase in MM-MM cell adhesion. For case 
2, we see an increase in tumor burden, decrease in EMDR, and increase in Melphalan resistance 
between BMBx3 and 5. FISH progresses with the emergence and successful growth of clone 
1.1.2 and clustering appears to gradually increase across this time window. 
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Utilizing the ‘number of neighbors’ algorithm to quantify clustering phenotype across 11 
different patients exposed to 25 PKI’s in the 384-well plate ex vivo study (Silva et al In Review) 
allowed correlations to be determined between cell survival in the experiment (AUC %) and the 
mean number of neighbors for that well (Figure 3.4). A statistically significant non-zero slope 
shows such a correlation, which was present in two drugs in the panel, Melphalan and Linifanib. 
Significance of these findings suggests a phenotypic clustering mechanism of survival in 
response to these two chemotherapeutic agents. The remaining drugs showed a slope that did not 
significantly differ from zero, signifying that, although mechanisms of drug resistance may exist 
for these agents, MM-MM adhesion displays no indication of being one such mechanism. 
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3.5 Chapter Three Figures 
 
Figure 3.1: Case 1 Patient History, Phylogenetic Tree, and Clonal Dynamics. A) Clinical 
Patient History based on Serum Free Light Chain measurements over a period of time in months. 
Biopsies are labeled and noted by red circles, with plot colors corresponding to the therapeutic 
regimen shown in the key. B) Clonal dynamics developed using FISH reports across sequential 
biopsies. After abnormalities in each biopsy are analyzed and clonal results discovered, they are 
plotted as a column plot representing the appropriate percentage of tumor cells that make up each 
genetically mutated subpopulation. C) A phylogenetic tree is synthesized to further describe the 
clones present in panel B. These clones are listed with the abnormalities displayed beneath and 
are constructed based on the principle of maximum parsimony, understanding that increases in 
heterogeneity and complexity occur chronologically, while varying percentages given in FISH 
reports represent abnormalities present that may not be mutually exclusive between clonal 
subpopulations.  We see here that as tumor burden increases toward biopsies eight through ten, 
the genetic abnormalities become increasingly complex and represent a larger population of the 
tumor burden. (Case 1) 	
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Figure 3.2: Case 1 and 2 Clinical History and Response Predictions. A-B) Patient clinical 
history with tumor burden determined via SFLC. Biopsies are denoted by open circles and 
colored lines correspond to therapeutic agents shown in the legend. C-F) Ex vivo 
chemosensitivity determined across patient biopsies for several drugs with known 
pharmacokinetics. Panels C and D show the LD50 of each drug across treatment and panels E 
and F represent the minimum tumor burden expected within 90 days after computational 
modeling of patient response. Panels A, C, and E represent case 1 and panels B, D, and F 
represent case 2. 
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Figure 3.3: Case 2 Patient History, EMDR, FN, and Beta1 Scores. A) Patient clinical history 
based on M-spike measurements over a period of time in months. Biopsies are labeled and noted 
by red circles, with plot colors corresponding to the therapeutic regimen shown in the key. B) 
EMDR score based on a maximum value of 255 across patient biopsies. C) FN is scored 
independently in the CD138 positive and negative areas as well as the IHC slide as a whole. D) 
Integrin β1 scores are determined in the same manner as FN. All scores are normalized by 
CD138 negative region intensity. (Case 2) 
(2)	
(1)	
(5)	
(4)	
(3)	
A.	
B.	
C.	
D.	
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Figure 3.4: Case 1 and Case 2 Homologous MM-MM Adhesion and Clustering Analysis of 
Therapeutic Agents. A, B) Clustering, as determined by a ‘number of neighbors’ algorithm, is 
plotted with each dot representing a cell in the control well at time zero of the 384-well plate 
assay with mean and standard error as black line(s). C, D) Images of 384 well plate after patient 
cell seeding. Table) A cohort of 11 patients exposed to 25 PKI’s was analyzed using the 
clustering analysis algorithm. A linear trend between resultant cell death in the 384 well plate ex 
vivo assay was compared to the mean number of neighbors seen at time zero in the control wells. 
P-values, R squared correlation coefficient, and Pearson r values are reported for each drug, with 
the two significantly non-zero sloped drugs, Melphalan and Linifanib, plotted (E). X’s and 
squares represent two patients that underwent two sequential biopsies, both of which are plotted 
for both drugs, resulting in 13 final data points. 
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CHAPTER 4:  DISCUSSION 
 
4.1 Complex Genetic Mutation and Clonal Evolution as a Mechanism of Relapse and 
Cross-Resistance 
 Analyses in this chapter discuss the results of our work with respect to the different 
patient cases. Complete figures with all obtained data for these cases are present in the 
Supplemental Figures section of the Appendix. The specifics of high-risk genetic abnormalities 
as they pertain to drug resistance and therapy failure in MM have been well-explored47. 
However, the origins of these mutations in response to therapy, environmental factors, the effect 
of abnormality combinations, and the successful risk stratification based on these abnormalities 
remain particularly elusive in MM13. We see from the results of our phylogenetic trees and clonal 
dynamic determinations that although these mutations do in fact cause increased risk of relapse, 
the results are rarely equivalent regarding depth and duration of response (or lack thereof) and 
the development of cross-resistance to therapy. For example, in our cases 1 and 2, the patients 
were on the same therapeutic regimen of TH302, BTZ, DEX, both showed marginal response to 
the drug (BMBx8-10 in case 1 and BMBx4 to 5 in case 2), and both had over 90% presence of 
genetically abnormal clones. However, we see very little change in clonal dynamics for case 2 
and a complete clonal extinction event in case 1 where all clones present in BMBx10 are 
‘daughter’ clones of those present in BMBx8 with no trace of the ‘parent’ clones remaining. 
Also, in both of these time periods, ex vivo clinical predictions show varying cross-resistant 
tumors resulting from the therapy. Case 1 shows substantial increase in resistance to Bortezomib 
for which he/she was treated, but also a cross-resistance to Melphalan and CRM1i. In contrast, 
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case 2 showed development of cross-resistance to Melphalan, but an increased sensitivity to 
Bortezomib. Therefore, clinical therapeutic intervention decisions should not be based solely on 
genetic abnormality. Likewise, clonal dynamics is only one piece of the puzzle regarding drug 
resistance in MM. 
 Another point worth discussing is the observable evolutionary drive toward heterogeneity 
among tumor subpopulations instead of a bottleneck effect similar to BCR-ABL in chronic 
myeloid leukemia (CML)48. These speciation events most likely occur to improve the chance for 
survival of one of the clonal populations in the face of varying, dynamic therapeutic regimen. 
We can see from our results that once speciation leads to a superior clone in the face of a 
particular therapy, this clone grows very rapidly and overtakes other less fit clones as in case 2 
with clone 1.1.2 between BMBx2 and 4, and case 5 with clone 1.1.1.1 between BMBx1 and 2. 
 
4.2 Exploring the Inverse Trend Between Tumor Burden and EMDR 
Human MM cells, when adherent to bone marrow stromal cells, increase IL-6 secretion49. 
IL-6 receptors in turn promote production of Janus kinase (Jak)/STAT3, which is known to 
increase survival of patient cells under therapeutic conditions29,50-53. Shain et al. demonstrated 
that when FN binds to the Integrin α4/β1 dimer on the MM cell surface, the STAT-3 pathway is 
further stimulated by increased IL-6 production as a result of preloading gp130. These concepts 
are further articulated by our findings regarding the EMDR score. In cases 1 and 2, as treatment 
progresses, EMDR score begins to rise. However, both cases also show that once tumor burden 
increases dramatically during relapse, the EMDR scores decrease. 
We propose that this decrease is due to two primary factors. First, that ligation of integrin 
β1 on hematopoietic tumor cells can lead to arrest of the cell cycle54-58. And second, that there is 
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limited space in the perivascular niche of the BM, and as tumor burden increases to a size that is 
unsustainable within this area, cells must venture to less ideal locations with fewer stromal cells 
to promote IL-6 secretion. This also justifies why FN scores decrease at a more rapid rate than 
integrin β1 scores, since relocation of tumor cells away from stroma would have a more 
immediate effect on FN presence but a delayed decrease in integrin β1 levels in the MM cells. 
The rapid proliferation of tumor cells that causes this decrease in factors measured by EMDR 
score may be due in part to genetic evolution of more fit subpopulations as well as MM-MM cell 
interactions and clustering that create another mechanism of protection to certain treatments such 
as Melphalan and Linifanib, as mentioned in our results. In these cases, the surviving cells that 
do not contribute to EMDR score would grow faster and render the STAT3 pathway irrelevant to 
successful proliferation. 
 
4.3 Possible Advantages of MM-MM Cell Adhesion to Drug Resistance 
From clustering results across sequential patient biopsies, we see clearly the presence of 
MM cell clustering in two cases, while two others show no evidence of this phenotype at all. We 
propose that as EMDR score goes down and cells are forced to move to other areas of the bone 
marrow, clustering is one mechanism that promotes survival in the presence of chemotherapeutic 
agents. This is supported by a concurrent ‘desire’ for cells to become more genetically complex 
and improve resistance through this pathway. From the substantial correlation between high-risk 
genetic mutation and N-cadherin overexpression, the homologous adhesion of MM cells may 
contribute positively to genetic resistance as well41,43. This may help explain why in patients 
such as our Case 1, in which successfully developed complex genetic clones show an increased 
ability to survive therapy, the clustering phenotype has been circumvented, while in other cases 
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such as Case 2, MM-MM cell adhesion is a necessary step in survival when leaving the 
perivascular niche. 
Clustering results across 13 samples (from 11 patients) showed correlation between MM-
MM cell adherence and survival ex vivo while treated with Melphalan or Linifanib. Mechanisms 
of resistance to Melphalan in MM primary cells has been previously explored and significant 
findings relate cytogenetics, and adhesion to bone marrow stromal cells and FN to increased 
tumor survival while exposed to the drug59,60. MM-MM homologous interaction can further this 
drug resistance by means of cell cycle inhibition to allow improved DNA repair caused by 
alkylating agents43,61. As an ATP-competitive tyrosine kinase inhibitor, Linifanib is effective 
against active FMS-like receptor tyrosine kinase 3 (FLT3), other platelet derived growth factor 
receptors, and vascular endothelial growth factor receptors62. In vitro, Linifanib has caused 
inhibition of several downstream pathways of FLT3, including the Jak/STAT pathway and cell 
cycle regulators like Cyclin D and p27k63,64. However, no previous findings have been made 
relating MM cell aggregation to Linifanib drug resistance. 
 
4.4 Summary of Findings 
A summary of our findings is represented in Figure 4.1. This figure shows a 
representation of our proposed schematic of drug resistance evolution. The evolution of drug 
resistance begins in the microenvironment where MM cells receive the most protection from 
drug due to surrounding stromal cells and serum. As therapy is forced into the environment, cells 
begin mutating in a manner representative of natural selection. As mutations fail to protect cells 
outside of the perivascular niche, they are destroyed by therapeutic agents. However, once a path 
to successful resistance occurs through homologous MM-MM interaction or chromosomal 
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mutation, the cells being to survive irrespectively of niche location, causing EMDR score to drop 
as clustering occurs or highly complex, ‘best fit’, mutations occur within the cell. Another 
important finding suggests that development of resistance to a single agent is rarely the case. In 
fact, based on our results it is rare for cross-resistance not to occur, even to drugs that the patient 
has never been exposed to. This suggests that the evolution of drug resistance promotes such 
resistance in general, not necessarily to a predictable set of drugs. To make matters more 
complicated, each patient exhibits drug resistance evolution to different degrees through different 
mechanisms that result in different cross-resistances through time. It seems critical that precision 
medicine take hold to promote individualized therapy decisions for each patient afflicted with 
MM, bearing in mind that each line of therapy may promote resistance to others, even if they 
have remained foreign to the patient before that time. 
These findings suggest that a change in perspective regarding therapy decision may be 
necessary to optimize patient response and limit relapse. Perhaps treatment at high concentration 
that more quickly removes the non-resistant cells will simply provide a more conducive 
environment for those MM cells that have established improved resistance phenotypes to grow 
more quickly. It may be more beneficial, therefore, to limit the number of drugs utilized over 
time and present them in concentrations that will manage the growth of sensitive cells and inhibit 
more evolutionarily fit subpopulations from taking over the tumoral space. Such therapy 
interventions may lead to less dramatic tumor burden reductions initially, but may also prevent 
the rapid and nearly inevitable relapse that occurs in MM patients today. 
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4.5 Chapter Four Figures 
 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: The Whole Picture: A Summary of Findings. Circles outlined in solid blue 
represent living MM, while the dashed line and gray inside represent those that have succumbed 
to therapy (yellow lightning bolt). Black lines on the left represent stromal cells in the 
perivascular niche and black ‘fork’ shapes between MM represent the signaling factors that 
promote MM-MM adhesion resistance. The blue cell represents successful genetic mutation that 
allows survival and drug resistance regardless of location, showing that the ‘best’ fit for 
evolutionary survival has been achieved and suggests that relapse will occur. 
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APPENDIX A:  SUPPLEMENTAL FIGURES 
 
 Below are figures comprising all data collected for the seven patient cases analyzed in 
this manuscript. N/A signifies that the data was unavailable for collection, not excluded for 
ulterior means. 
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Figure A.1: Case 1 Patient History, Ex Vivo Results, FISH, and EMDR. 
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Figure A.2: Case 1 Clustering Analysis Results. 
33 
		
Figure A.3: Case 2 Patient History, Ex Vivo Results, FISH, and EMDR. 	
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Figure A.4: Case 2 Clustering Analysis Results. 
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Figure A.5: Case 3 Patient History, Ex Vivo Results, FISH, and EMDR. 			 		
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Figure A.6: Case 3 Clustering Analysis Results. 
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Figure A.7: Case 4 Patient History, FISH, and EMDR. 		
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Figure A.8: Case 5 Patient History, FISH, and EMDR. 
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Figure A.9: Case 6 Patient History. 						 	
Figure A.10: Case 6 Clustering Analysis Results. 
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Figure A.11: Case 7 Patient History and FISH. 	
 
